Zydus Lifesciences Turns Green After Three-Day Slide

As on 10 Dec 2025,

closed marginally higher by 0.3% after logging three consecutive negative sessions. The mild recovery came amid a key corporate development. The company’s UAE-based subsidiary, Zydus Lifesciences Global FZE, entered into a strategic partnership with Formycon AG for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab), for the US and Canadian markets. The update brought fresh attention to the stock after recent weakness, with market participants tracking how prices respond around current levels. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. ChatGPT may have been used for grammatical and sentence-structure refinement. Please consult a SEBI-registered advisor before making any investment decisions.